JPMorgan Chase & Co. Lowers Evolent Health (NYSE:EVH) Price Target to $15.00

Evolent Health (NYSE:EVH) had its price target cut by JPMorgan Chase & Co. from $45.00 to $15.00 in a research report released on Friday,Benzinga reports. They currently have an overweight rating on the technology company’s stock.

EVH has been the subject of a number of other research reports. Oppenheimer decreased their target price on Evolent Health from $34.00 to $28.00 and set an “outperform” rating for the company in a report on Monday, November 18th. Truist Financial reaffirmed a “buy” rating and set a $33.00 price objective on shares of Evolent Health in a research report on Tuesday, August 27th. Stephens cut Evolent Health from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $38.00 to $16.00 in a research report on Friday, November 8th. Citigroup dropped their price objective on Evolent Health from $33.00 to $21.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Finally, KeyCorp assumed coverage on Evolent Health in a research report on Friday, October 11th. They set an “overweight” rating and a $35.00 price objective on the stock. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $25.90.

Evolent Health Stock Performance

Shares of EVH stock opened at $12.22 on Friday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. Evolent Health has a fifty-two week low of $11.17 and a fifty-two week high of $35.00. The stock has a 50 day moving average price of $22.89 and a two-hundred day moving average price of $23.64. The company has a market capitalization of $1.42 billion, a P/E ratio of -13.42 and a beta of 1.58.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Royce & Associates LP bought a new position in Evolent Health in the third quarter valued at about $7,070,000. Harbor Capital Advisors Inc. raised its stake in shares of Evolent Health by 140.0% in the third quarter. Harbor Capital Advisors Inc. now owns 422,421 shares of the technology company’s stock worth $11,946,000 after buying an additional 246,400 shares during the period. Foundry Partners LLC bought a new position in shares of Evolent Health in the third quarter worth about $10,042,000. Price T Rowe Associates Inc. MD raised its stake in shares of Evolent Health by 11.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 717,334 shares of the technology company’s stock worth $23,522,000 after buying an additional 75,376 shares during the period. Finally, Valeo Financial Advisors LLC bought a new position in shares of Evolent Health in the second quarter worth about $2,705,000.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.